Glenmark obtains DCGI nod for clinical study of its GRC 54276 molecule

By Akshay Kedari  | Date: 2022-04-12

Glenmark obtains DCGI nod for clinical study of its GRC 54276 molecule

Glenmark Pharmaceuticals Limited has reportedly received approval from the DCGI (Drug Controller General of India) to perform phase 1 clinical trials of its novel molecule for advanced solid tumor patients.

Glenmark Specialty SA obtained the DCGI nod for GRC 54276, the company’s novel small molecule which is an HPK1 (hematopoietic progenitor kinase 1) inhibitor.

For those unaware, GRC 54276 is one of the several novel molecules from the company’s Innovative Medicines Group which specializes in the development of advanced molecular entities for crucial unsatisfied medical needs.

Speaking about the molecule, Glenmark stated that GRC 54276 has showcased the ability to eliminate tumour cells in preclinical studies through combination with checkpoint inhibitors as well as a single agent, further marking it as a key target in immuno-oncology.

The study will assess the tolerability and safety of GRC 54276 in combination with checkpoint inhibitors and as a monotherapy in patients with Hodgkin's lymphoma and advanced solid tumours.

Glenmark cited that it will commence Phase 1 clinical trial in India by June this year and intends to file an Investigational New Drug (IND) application in the United States as well as a clinical trial application in Europe to initiate a global clinical study program.

Glenn Saldanha, the Chairman & Managing Director of Glenmark Pharmaceuticals, believes that the clinical study approval of the novel molecule, which is a part of the newly established Innovative Medicines Group within the organization, will strengthen the company’s growth abilities of innovative clinical research and allow it to offer comprehensive cancer treatment solutions.

It is worth noting that Glenmark has a presence across generics, specialty, and OTC businesses. The company focuses on crucial therapeutic areas of oncology, dermatology, and respiratory. The company has nearly 10 manufacturing facilities across four continents and operates in more than 80 countries.

Source credits:

https://www.business-standard.com/article/pti-stories/glenmark-receives-dcgi-nod-to-conduct-clinical-trials-of-its-molecule-on-cancer-patients-122041100273_1.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Hyundai’s U.S. investment expected to reach USD 10 billion by 2025

Hyundai’s U.S. investment expected to reach USD 10 billion by 2025

By Akshay Kedari

South Korea's largest carmaker Hyundai Motor Group is reportedly planning to invest an additional USD 5 billion in the U.S. by 2025. The company aims to strengthen its collaboration with technological firms in the country. During a visit to Se...

Amazon Smart Commerce to digitize 10 million small businesses in India

Amazon Smart Commerce to digitize 10 million small businesses in India

By Akshay Kedari

E-commerce behemoth Amazon Inc. has reportedly launched a “Smart Commerce” initiative in India, aiming to digitalize 10 million small businesses, allow for USD 10 billion worth in exports, and create 2 million jobs by 2025. During the ...

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

By Akshay Kedari

After Ukraine’s invasion, multinational fast-food giant McDonald's Corp. is reportedly planning to sell all its restaurants in Russia, pulling operations from the nation after 30 years. The world's biggest fast-food chain closed 847 ...

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

By Akshay Kedari

GetHenry, a Berlin-based company that offers couriers and logistics organizations electric last-mile delivery bikes, has reportedly raised USD 17.4 million seed round to grow its operations across Europe. The latest investment round was led by LocalG...

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

By Akshay Kedari

Italian luxury sports car manufacturer Ferrari S.p.A. will equip its much-awaited Purosangue SUV with a 12-cylinder engine, as it focused more on fuel-efficient models. Confirming the news, Ferrari Chief Executive Benedetto Vigna claimed that the com...